Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.49 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.49 |
| ▸ | NOS3 | P29474 | 4/20 | 0.43 |
| ▸ | NOS1 | P29475 | 4/20 | 0.43 |
| ▸ | NOS2 | P35228 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | THPO | P40225 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CHAT | P28329 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | GMNN | O75496 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4540358 | 1.00 | RAB9A (0.49) | RAB9AKDM4EAPOBEC3AAPOBEC3GNOS3 | |
| SCHEMBL4533703 | 0.81 | RAB9A (0.49) | RAB9AKDM4EAPOBEC3AAPOBEC3GMEN1 | |
| SCHEMBL4533699 | 0.81 | RAB9A (0.49) | RAB9AKDM4EAPOBEC3AAPOBEC3GMEN1 | |
| SCHEMBL5865516 | 0.79 | CYP19A1 (0.53) | KDM4ENOS3NOS1NOS2MEN1 | |
| SCHEMBL5865513 | 0.79 | CYP19A1 (0.53) | KDM4ENOS3NOS1NOS2MEN1 | |
| SCHEMBL31380868 | 0.79 | CYP19A1 (0.53) | KDM4ENOS3NOS1NOS2MEN1 | |
| SCHEMBL8215767 | 0.75 | RAB9A (0.56) | RAB9AKDM4EAPOBEC3AAPOBEC3GMEN1 | |
| SCHEMBL20741512 | 0.75 | RAB9A (0.49) | RAB9AKDM4EAPOBEC3AAPOBEC3GMEN1 | |
| SCHEMBL20741511 | 0.75 | RAB9A (0.49) | RAB9AKDM4EAPOBEC3AAPOBEC3GMEN1 | |
| SCHEMBL30176184 | 0.75 | RAB9A (0.49) | RAB9AKDM4EAPOBEC3AAPOBEC3GMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722709-B2 | Mineralocorticoid receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-05-13 | — | — | US | disclosed |
| US-8722709-B2 | Mineralocorticoid receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-05-13 | — | — | US | disclosed |
| EP-2638012-A1 | PYRIDYL UREAS AS MINERALOCORTICOID RECEPTOR ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2013-09-18 | — | — | EP | disclosed |
| US-20120289551-A1 | MINERALOCORTICOID RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2012-11-15 | — | — | US | disclosed |
| US-20120289551-A1 | MINERALOCORTICOID RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2012-11-15 | — | — | US | disclosed |
| WO-2012064631-A1 | PYRIDYL UREAS AS MINERALOCORTICOID RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289551-A1 | MINERALOCORTICOID RECEPTOR ANTAGONISTS | NR3C2, MC2R, AVPR2 | RAB9A 4417/4885KDM4E 4212/4885APOBEC3A 4814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.